Latest Breaking News On - Irving investors - Page 10 : comparemela.com

InterVenn Biosciences, a South San Francisco, Calif.-based company that utilizes a proprietary glycoproteomics biomarker interrogation platform using AI and mass spectrometry for next-gen precision medicine, completed a $201m Series C financing. The round was led by new investors SoftBank Group, Heritage Provider Network, Irving Investors, Highside Capital Management, and backed by existing investors Amplify Partners, Anzu Partners, Genoa Ventures and True Ventures. The company intends to use the funds to accelerate development and commercialization of Dawn™, a liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on its AI-driven glycoproteomics platform to accelerate development and commercialization of new clinical solutions, and broaden insights into new biomarkers and therapies.

Intervenn biosciencesAldo carrascosoSoftbank groupHeritage provider networkSouth san franciscoIrving investorsHighside capital managementAmplify partnersAnzu partnersGenoa venturesChief executive officerசாப்ட் பேங்க் குழுபாரம்பரியம் வழங்குநர் வலைப்பின்னல்தெற்கு சான் பிரான்சிஸ்கோஇவிஂக் முதலீட்டாளர்கள்ஹைசைடு மூலதனம் மேலாண்மை